Cargando…
Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTV...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471561/ https://www.ncbi.nlm.nih.gov/pubmed/34575362 http://dx.doi.org/10.3390/jcm10184252 |
_version_ | 1784574498619523072 |
---|---|
author | Cepas-Guillen, Pedro Luis de la Fuente Mancera, Juan Carlos Guzman Bofarull, Joan Farrero, Marta Regueiro, Ander Brugaletta, Salvatore Ibañez, Cristina Sanchis, Laura Sitges, Marta Sabate, Manel Freixa, Xavier |
author_facet | Cepas-Guillen, Pedro Luis de la Fuente Mancera, Juan Carlos Guzman Bofarull, Joan Farrero, Marta Regueiro, Ander Brugaletta, Salvatore Ibañez, Cristina Sanchis, Laura Sitges, Marta Sabate, Manel Freixa, Xavier |
author_sort | Cepas-Guillen, Pedro Luis |
collection | PubMed |
description | Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events. Results: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up; p < 0.001). Echocardiography follow-up showed residual TR ≤ 2 in 79% of patients (paired p < 0.001). At the maximum follow-up (median follow up = 372 days), no patients had died. Conclusions: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety. |
format | Online Article Text |
id | pubmed-8471561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84715612021-09-28 Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program Cepas-Guillen, Pedro Luis de la Fuente Mancera, Juan Carlos Guzman Bofarull, Joan Farrero, Marta Regueiro, Ander Brugaletta, Salvatore Ibañez, Cristina Sanchis, Laura Sitges, Marta Sabate, Manel Freixa, Xavier J Clin Med Article Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events. Results: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up; p < 0.001). Echocardiography follow-up showed residual TR ≤ 2 in 79% of patients (paired p < 0.001). At the maximum follow-up (median follow up = 372 days), no patients had died. Conclusions: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety. MDPI 2021-09-19 /pmc/articles/PMC8471561/ /pubmed/34575362 http://dx.doi.org/10.3390/jcm10184252 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cepas-Guillen, Pedro Luis de la Fuente Mancera, Juan Carlos Guzman Bofarull, Joan Farrero, Marta Regueiro, Ander Brugaletta, Salvatore Ibañez, Cristina Sanchis, Laura Sitges, Marta Sabate, Manel Freixa, Xavier Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title | Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title_full | Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title_fullStr | Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title_full_unstemmed | Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title_short | Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program |
title_sort | initial results after the implementation of an edge-to-edge transcatheter tricuspid valve repair program |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471561/ https://www.ncbi.nlm.nih.gov/pubmed/34575362 http://dx.doi.org/10.3390/jcm10184252 |
work_keys_str_mv | AT cepasguillenpedroluis initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT delafuentemancerajuancarlos initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT guzmanbofarulljoan initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT farreromarta initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT regueiroander initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT brugalettasalvatore initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT ibanezcristina initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT sanchislaura initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT sitgesmarta initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT sabatemanel initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram AT freixaxavier initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram |